Lung Neoplasm

Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
1 program
1
R-DXDPhase 21 trial
Active Trials
NCT06780098Recruiting144Est. Mar 2032
Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
1
BLU-701Phase 11 trial
Active Trials
NCT05153408Terminated20Est. Dec 2022
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
LungPoint Virtual Bronchoscopic NavigationN/A1 trial
Active Trials
NCT01067755Unknown60Est. Mar 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Daiichi SankyoR-DXD
Blueprint MedicinesBLU-701
Heidelberg PharmaLungPoint Virtual Bronchoscopic Navigation

Clinical Trials (3)

Total enrollment: 224 patients across 3 trials

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

Start: May 2025Est. completion: Mar 2032144 patients
Phase 2Recruiting

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Start: Jan 2022Est. completion: Dec 202220 patients
Phase 1Terminated
NCT01067755Heidelberg PharmaLungPoint Virtual Bronchoscopic Navigation

Evaluation of the LungPoint Virtual Bronchoscopic Navigation (VBN) System

Start: Jul 2009Est. completion: Mar 201160 patients
N/AUnknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 224 patients
3 companies competing in this space